Platinib Capsule Price Forecast and Market Overview in 2024

Pralsetinib (Pralsetinib), as a precision treatment drug for RET mutated tumors, has a unique mechanism to curb the development of tumors by inhibiting the activity of RET kinase. In the medical community, it has been recognized as a breakthrough in the treatment of non-small cell lung cancer (NSCLC) and thyroid cancer, especially providing new hope for patients who have failed to respond to traditional treatments.

However, the high cost of medications has always been a concern for patients and their families. At present, the standard specification of platinib in the domestic market is 100mg*120 pills per box, and its price is astonishing, as high as about 60,000 yuan. Since this drug is not yet covered by medical insurance policies, patients need to bear all costs themselves, which undoubtedly increases the financial pressure on patients.

Turning to the international market, the price of platinib also showed large fluctuations. The European and American versions have a specification of 100mg*60 capsules per box, and their prices fluctuate in the range of 40,000 to 150,000 yuan, affected by a variety of factors, among which exchange rate fluctuations are particularly significant. This uncertainty makes patients face more difficulties and risks when seeking to purchase drugs overseas.

But the market is always full of variables. In recent years, generic drugs of platinib have gradually emerged. Take platinib produced by a Lao pharmaceutical factory as an example. Its ingredients are highly similar to the original drug, but its price is very different. The price of platinib with the same specifications is only over 4,000 yuan, which undoubtedly provides patients with a more affordable choice.

Looking forward, the market structure of platinib and its generic drugs is still full of uncertainties. On the one hand, with the advancement of technology and market competition, the production cost of drugs is expected to gradually decrease; on the other hand, government policy support and the improvement of the medical insurance system will also have a profound impact on drug prices. We hope that in the near future, innovative drugs such as Platinib will become more accessible and benefit more patients.